JP2023113751A5 - - Google Patents

Download PDF

Info

Publication number
JP2023113751A5
JP2023113751A5 JP2023088154A JP2023088154A JP2023113751A5 JP 2023113751 A5 JP2023113751 A5 JP 2023113751A5 JP 2023088154 A JP2023088154 A JP 2023088154A JP 2023088154 A JP2023088154 A JP 2023088154A JP 2023113751 A5 JP2023113751 A5 JP 2023113751A5
Authority
JP
Japan
Prior art keywords
formulation
salt
amino acids
chloride
anions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023088154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023113751A (ja
Filing date
Publication date
Priority claimed from JP2021167771A external-priority patent/JP7338890B2/ja
Application filed filed Critical
Publication of JP2023113751A publication Critical patent/JP2023113751A/ja
Publication of JP2023113751A5 publication Critical patent/JP2023113751A5/ja
Pending legal-status Critical Current

Links

JP2023088154A 2014-05-28 2023-05-29 Tat-NR2B9cの塩化物塩 Pending JP2023113751A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004142P 2014-05-28 2014-05-28
US62/004,142 2014-05-28
JP2021167771A JP7338890B2 (ja) 2014-05-28 2021-10-13 Tat-NR2B9cの塩化物塩

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021167771A Division JP7338890B2 (ja) 2014-05-28 2021-10-13 Tat-NR2B9cの塩化物塩

Publications (2)

Publication Number Publication Date
JP2023113751A JP2023113751A (ja) 2023-08-16
JP2023113751A5 true JP2023113751A5 (cg-RX-API-DMAC7.html) 2023-11-30

Family

ID=54698210

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016569655A Expired - Fee Related JP6622222B2 (ja) 2014-05-28 2015-05-28 Tat−NR2B9cの塩化物塩
JP2019210223A Expired - Fee Related JP6961661B2 (ja) 2014-05-28 2019-11-21 Tat−NR2B9cの塩化物塩
JP2021167771A Active JP7338890B2 (ja) 2014-05-28 2021-10-13 Tat-NR2B9cの塩化物塩
JP2023088154A Pending JP2023113751A (ja) 2014-05-28 2023-05-29 Tat-NR2B9cの塩化物塩

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2016569655A Expired - Fee Related JP6622222B2 (ja) 2014-05-28 2015-05-28 Tat−NR2B9cの塩化物塩
JP2019210223A Expired - Fee Related JP6961661B2 (ja) 2014-05-28 2019-11-21 Tat−NR2B9cの塩化物塩
JP2021167771A Active JP7338890B2 (ja) 2014-05-28 2021-10-13 Tat-NR2B9cの塩化物塩

Country Status (27)

Country Link
US (4) US10206973B2 (cg-RX-API-DMAC7.html)
EP (2) EP3757134B1 (cg-RX-API-DMAC7.html)
JP (4) JP6622222B2 (cg-RX-API-DMAC7.html)
KR (3) KR102605540B1 (cg-RX-API-DMAC7.html)
CN (2) CN106661126B (cg-RX-API-DMAC7.html)
AU (2) AU2015265487B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016027814A2 (cg-RX-API-DMAC7.html)
CA (1) CA2950395C (cg-RX-API-DMAC7.html)
CY (1) CY1122793T1 (cg-RX-API-DMAC7.html)
DK (1) DK3149048T3 (cg-RX-API-DMAC7.html)
ES (2) ES2974228T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200462T1 (cg-RX-API-DMAC7.html)
HU (1) HUE049074T2 (cg-RX-API-DMAC7.html)
IL (1) IL249252B (cg-RX-API-DMAC7.html)
LT (1) LT3149048T (cg-RX-API-DMAC7.html)
ME (1) ME03790B (cg-RX-API-DMAC7.html)
MX (2) MX374958B (cg-RX-API-DMAC7.html)
PL (1) PL3149048T3 (cg-RX-API-DMAC7.html)
PT (1) PT3149048T (cg-RX-API-DMAC7.html)
RS (1) RS60625B1 (cg-RX-API-DMAC7.html)
RU (2) RU2019138024A (cg-RX-API-DMAC7.html)
SG (2) SG11201609911YA (cg-RX-API-DMAC7.html)
SI (1) SI3149048T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000307T1 (cg-RX-API-DMAC7.html)
UA (1) UA123820C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015181756A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201608843B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
UA123820C2 (uk) 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
CA2950392A1 (en) 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
KR102403089B1 (ko) 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
AU2021206472A1 (en) * 2020-01-09 2022-08-18 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
CN111560050A (zh) * 2020-05-25 2020-08-21 成都圣诺生物制药有限公司 一种Nerinetide的制备方法
EP4274596A4 (en) 2021-01-08 2024-12-25 NoNO Inc. Plasmin-resistant peptides for improved therapeutic index
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
EP4706670A1 (en) 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
WO2026012336A1 (zh) * 2024-07-08 2026-01-15 福建盛迪医药有限公司 一种psd-95多肽抑制剂的可药用盐及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US9101590B2 (en) * 2005-07-29 2015-08-11 Yale University Defined culture conditions of human embryonic stem cells
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
ES2446292T3 (es) 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
PL2320927T3 (pl) * 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
CA2765169C (en) * 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
US9629892B2 (en) * 2010-08-12 2017-04-25 Nono Inc. Treatment of penetrative injury to the brain
WO2012050921A2 (en) * 2010-09-28 2012-04-19 Nono, Inc. Nd2 peptides and methods of treating neurological disease
KR102046830B1 (ko) * 2011-05-13 2019-11-20 코벤하븐스 유니버시테트 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 psd-95의 고-친화성, 이량체 저해제
CN102241745A (zh) * 2011-05-19 2011-11-16 南京医科大学 多肽类似物Tat-HA-NR2B9C及其制备方法和应用
HRP20220519T1 (hr) * 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
AU2012354072B2 (en) 2011-12-13 2017-04-27 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
TR201905787T4 (tr) 2012-11-28 2019-05-21 Nono Inc Liyofilize TAT-NR2B9C formülasyonu.
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
UA123820C2 (uk) 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
CA2950392A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger

Similar Documents

Publication Publication Date Title
JP3533216B2 (ja) 乳頭腫ウイルスl2蛋白
JP2022517399A5 (cg-RX-API-DMAC7.html)
JP2022166006A5 (cg-RX-API-DMAC7.html)
JP2024503265A5 (cg-RX-API-DMAC7.html)
IL240686A (en) Preparations containing cyclic peptides containing adjacent arginine residues
US9181303B2 (en) Treatment of bacterial infections with cyclic antimicrobial peptides
JP2021521159A5 (cg-RX-API-DMAC7.html)
JP2018512454A5 (cg-RX-API-DMAC7.html)
JP2022088521A5 (cg-RX-API-DMAC7.html)
EP1985625B1 (en) Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis
JP2023529839A5 (cg-RX-API-DMAC7.html)
JP2017517517A5 (cg-RX-API-DMAC7.html)
JP2021526505A5 (cg-RX-API-DMAC7.html)
WO2016046523A1 (en) Use of cystamine for treating bacterial and fungal infections
JP2021527647A (ja) エキノカンジン抗真菌剤の合成
CN116406286A (zh) 免疫调节化合物及其用于治疗和/或预防传染性疾病的用途
JP5403867B2 (ja) 急速分散性医薬固形剤形における食用酸の使用
JP2026506447A (ja) 呼吸器合胞体ウイルスmRNAワクチン
JP2001524083A (ja) テイコプラニン誘導体
CZ2002540A3 (cs) Farmaceutické činidlo obsahující benzamidový derivát jako aktivní sloľku
KR20220034053A (ko) 재조합 단백질의 안정적인 제형
EP0560969B1 (fr) Vaccin comprenant une sous-unité du récepteur de la transferrine humaine tel qu'isolé de Neisseria meningitidis
JP2021518443A5 (cg-RX-API-DMAC7.html)
AU764061B2 (en) Use of active P40 conjugates for nasal delivery
JP2021521168A5 (cg-RX-API-DMAC7.html)